Bill Miller, LMM chairman & CIO, weighs in on why he likes auto stocks and biotech company Intrexon.
Michel Demaré, chairman of Syngenta, says the takeover deal with state-owned ChemChina is good value for shareholders.
Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.
After rash of earnings reports, Abbott Labs, Bristol-Myers Squibb, Celgene and Eli Lilly shares suffer. CNBC's Meg Tirrell reports.
JMP Securities President Mark Lehmann explains why now is the time to get in on biotech stocks.
Celgene's Mark Hugin is replaced by Mark Alles as CEO, and the company lowers earnings estimates, reports CNBC's Sue Herera.
Novartis CEO Joe Jimenez says the pharma industry needs to rethink pricing as drug combinations are increasingly being used to treat cancer and other diseases.
Eli Lilly's John Lechleiter says he's optimistic about the year ahead for the pharmaceuticals industry, including measures to help patients afford prescription drugs.
Eli Lilly CEO John Lechleiter discusses clinical trials of his company's treatments for Alzheimer's disease.
Activist investor Bill Ackman's Pershing Square Capital Management is cutting its stake in Valeant Pharmaceuticals, reports CNBC's Seema Mody.
A Chinese firm that's building the world's biggest animal cloning factory has vowed not to use the technology on people—for now. NBCNews reports.
GlaxoSmithKline CEO Sir Andrew Witty discusses the drug environment as pressure mounts over higher prices.
GlaxoSmithKline CEO Sir Andrew Witty weighs in on why his company has no immediate deal plans in the drug space.
U.S. prosecutors are probing Valeant Pharmaceuticals over how it prices and distributes drugs, the Canadian pharma giant revealed late Wednesday.
And artificial intelligence will be hot for Chinese consumers, but 3-D printing will be all the rage in Europe.
James West, senior healthcare analyst for Results Healthcare, talks about biotech stocks and explains the differences biotech and pharmaceutical companies.
Bill Doyle, Executive Chairman, NovoCure, discusses the company's difficult debut--shares opened at $20.16, below the $22 IPO price.
With health care, financials and energy sectors all embattled, what should investors expect going into the fourth quarter and 2016?
Biotech's have had a very bad week, but the IBB has recovered a bit today. What's behind all the volatility, with Fed Hassan, Warburg Pincus, and CNBC's Meg Tirrell.
With the biotechnology sector tumbling, is this temporary? Or the beginning of a downward slide? Analysts weigh in.